Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Here’s What Happened

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up before the market opened on Thursday . The stock had previously closed at $18.99, but opened at $20.49. Ascentage Pharma Group International shares last traded at $20.4250, with a volume of 1,047 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have commented on AAPG. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 target price for the company. BTIG Research reissued a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Finally, China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $46.67.

Ascentage Pharma Group International Price Performance

The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. The stock’s 50-day moving average is $23.59 and its two-hundred day moving average is $26.34.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $24.72 million for the quarter. Research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current year.

Hedge Funds Weigh In On Ascentage Pharma Group International

Hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ascentage Pharma Group International during the third quarter worth $96,000. ABC Arbitrage SA bought a new position in Ascentage Pharma Group International during the third quarter valued at $204,000. Citadel Advisors LLC bought a new position in Ascentage Pharma Group International during the third quarter valued at $383,000. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International during the second quarter valued at $391,000. Finally, XY Capital Ltd lifted its position in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares during the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.